The abstract is read at the publisher; the summary is JClub's.
A deep mutational scan of full-length Lck maps how nearly all single kinase-domain substitutions affect phosphotransferase activity and inhibitor sensitivity, enabling engineered pharmacological control.
- Why it matters: Selectively tuning small-molecule responsiveness without breaking native kinase function is a key bottleneck for engineering cell-based immunotherapies.
- What they did: They profiled phosphotransferase activity for nearly all single amino acid substitutions in Lck, then screened each variant for sensitization to dabrafenib, erlotinib, gefitinib, imatinib, and nilotinib.
- The result: Integrating activity and sensitization landscapes identified a nilotinib-sensitized Lck variant, I312S, that supports TCR signaling and, with drug, selectively suppresses proximal signaling and IL-2 production in Jurkat cells despite endogenous Lck.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.